AUTHOR=Nie Jiayan , Zhao Qiu 

TITLE=Lnc-ITSN1-2, Derived From RNA Sequencing, Correlates With Increased Disease Risk, Activity and Promotes CD4+ T Cell Activation, Proliferation and Th1/Th17 Cell Differentiation by Serving as a ceRNA for IL-23R via Sponging miR-125a in Inflammatory Bowel Disease

JOURNAL=Frontiers in Immunology

VOLUME=11

YEAR=2020

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.00852

DOI=10.3389/fimmu.2020.00852

ISSN=1664-3224

ABSTRACT=<p><bold>Background:</bold> This study aimed to investigate long-non-coding RNA (lncRNA) expression profiles and the correlation of lnc-ITSN1-2 expression with disease risk, activity and inflammation, and its influence on CD4<sup>+</sup> T cell activation, proliferation, and differentiation of inflammatory bowel disease (IBD).</p><p><bold>Methods:</bold> LncRNA expression profiles were detected in intestinal mucosa samples from six IBD patients and six healthy controls (HCs). Intestinal mucosa and PBMC lnc-ITSN1-2, IL-23R, and inflammatory cytokines were measured in 120 IBD patients [60 Crohn's disease (CD) and 60 ulcerative colitis (UC)] and 30 HCs. Effect of lnc-ITSN1-2 on IBD CD4<sup>+</sup> T cell activation, proliferation, and differentiation was determined and its regulatory interaction with miR-125a and IL-23R was detected.</p><p><bold>Results:</bold> Three-hundred-and-nine upregulated and 310 downregulated lncRNAs were identified in IBD patients by RNA-Sequencing, which were enriched in regulating immune and inflammation related pathways. Large-sample qPCR validation disclosed that both intestinal mucosa and PBMC lnc-ITSN1-2 expressions were increased in IBD patients compared to HCs, and presented with good predictive values for IBD risk, especially for active disease conditions, and they positively correlated with disease activity, inflammation cytokines, and IL-23R in IBD patients. Lnc-ITSN1-2 was decreased after infliximab treatment in active-CD patients. Furthermore, lnc-ITSN1-2 promoted IBD CD4<sup>+</sup> T cell activation and proliferation, and stimulated Th1/Th17 cell differentiation. Multiple rescue experiments disclosed that lnc-ITSN1-2 functioned in IBD CD4<sup>+</sup> T cells via targeting miR-125a, then positively regulating IL-23R. Luciferase Reporter assay observed that lnc-ITSN1-2 bound miR-125a, and miR-125a bound IL-23R.</p><p><bold>Conclusion:</bold> Lnc-ITSN1-2 correlates with increased disease risk, activity, and inflammatory cytokines of IBD, and promotes IBD CD4<sup>+</sup> T cell activation, proliferation, and Th1/Th17 cell differentiation by serving as a competing endogenous RNA for IL-23R via sponging miR-125a.</p>